Cohance Lifesciences Limited — Updates, 07-12-2024: Press Release

Suven Pharmaceuticals Limited has made a strategic move by acquiring a controlling stake in NJ Bio, Inc. for approximately $64.4 million, which positions them as a leader in the rapidly growing Antibody-Drug Conjugates (ADC) market. NJ Bio, a US-based Contract Research and Development Manufacturing Organization (CRDMO), specializes in ADC/XDC with end-to-end capabilities. This acquisition enhances Suven's competencies, expanding its addressable market from approximately $200 million to about $1.4 billion, projected to grow at over 20% annually.

NJ Bio's robust pipeline includes a projected revenue of $32 million for CY24, reflecting a 70% compound annual growth rate since CY21. The acquisition will also bolster Suven's existing capabilities in payload-linker chemistry and bioconjugation, leveraging NJ Bio’s state-of-the-art facility in Princeton, which serves a complementary customer base across the biotech and pharma sectors. The deal, anticipated to be accretive to earnings within two years, presents a positive outlook for Suven as it aims to establish a comprehensive technology-driven CDMO platform. Shareholders and potential investors should note this significant expansion into a high-growth segment and the synergistic benefits that may arise from this acquisition.